Susana S. Najera

Susana S. Najera

Auto-generated profile, based on publicly available information

Susana S. Najera

Office of Gene Therapy, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
SNSusana S. Najera
Susana S. Najera
Christopher J. RickettsChristopher J. Ricketts
Christopher J. Ricketts
LSLaura S. Schmidt
Laura S. Schmidt
JMJulia I. Medina
Julia I. Medina
KSKeita Saito
Keita Saito
JMJordan L. Meier
Jordan L. Meier
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an inherited cancer syndrome caused by germline pathogenic variants in the fumarate hydratase (FH) gene. Affected individuals are at risk for developing cutaneous and uterine leiomyomas and aggressive FH-deficient renal cell carcinoma (RCC) with a papillary histology. Due to a disrupted tricarboxylic acid cycle, FH-deficient kidney cancers rely on aerobic glycolysis for energy production, potentially creating compensatory metabolic vulnerabilities. This study conducted a high-throughput drug screen in HLRCC cell lines, which identified a critical dependency on nicotinamide adenine dinucleotide (NAD), a redox cofactor produced by the biosynthetic enzyme nicotinamide phosphoribosyltransferase (NAMPT). Human HLRCC tumors and HLRCC-derived cell lines exhibited elevated NAMPT expression compared with controls. FH-deficient HLRCC cells, but not FH-restored HLRCC or normal kidney cells, were sensitive to NAMPT inhibition. HLRCC cell line viability was significantly decreased in both 2D and 3D in vitro cultures in response to the clinically relevant NAMPT inhibitor OT-82. NAMPT inhibition in vitro significantly decreased the total amount of NAD+, NADH, NADP, NADPH, and poly-ADP-ribose levels, and the effects of NAMPT inhibition could be rescued by the downstream NAD precursor nicotinamide mononucleotide (NMN), confirming the on-target activity of OT-82. Moreover, NAMPT inhibition by OT-82 in two HLRCC xenograft models resulted in severely reduced tumor growth. OT-82 treatment of HLRCC xenograft tumors in vivo inhibited glycolytic flux as demonstrated by reduced lactate/pyruvate ratio in hyperpolarized 13C-pyruvate magnetic resonance spectroscopic imaging experiments. Overall, our data define NAMPT inhibition as a potential therapeutic approach for FH-deficient HLRCC-associated RCC.

3 March 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSojin Bing
Sojin Bing
AEArya Eskandarian
Arya Eskandarian
SSSean Smith
Sean Smith
ASAbdul Mohin Sajib
Abdul Mohin Sajib
SWStephanee Warrington
Stephanee Warrington
RMRonit Mazor
Ronit Mazor
Adeno-associated virus (AAV) vectors are widely used in gene therapy, but their immunogenicity remains a significant challenge, limiting long-term efficacy and the feasibility of repeated administration. In this study, we combine computational prediction with experimental validation to engineer AAV9 capsids with reduced immunogenicity. To facilitate this, we developed the Epitope Modification and MHC Prediction (EMMP) pipeline, which systematically automates the evaluation of amino acid substitutions for their predicted effects on major histocompatibility complex (MHC) presentability. Using this pipeline, we modify a CD4⁺ T-cell epitope in the AAV9 capsid that is identified and characterized as a proof-of-concept. Two mutant variants, R312H and R312Q, are selected and evaluated for transduction efficiency in vitro and immune response modulation in vivo. Notably, R312Q shows a significant reduction in T-cell activation and anti-AAV9 antibody production, albeit with a slight reduction in transduction at low multiplicities of infection (MOI). These results demonstrate a rational approach for optimizing AAV vector design, with potential applications for improving the safety and efficacy of gene therapy.

4 February 2025
Verified
Other
Open access
PDF file
SNSusana S. Najera
Susana S. Najera
Christopher J. RickettsChristopher J. Ricketts
Christopher J. Ricketts
LSLaura S. Schmidt
Laura S. Schmidt
JMJulia I. Medina
Julia I. Medina
KSKeita Saito
Keita Saito
JMJordan L. Meier
Jordan L. Meier
Real-time invasion analysis of UOK262 and UOK365 cells treated with OT-82. Real-time invasion analysis of UOK262 and UOK365 cells demonstrating cell line invasion over 5 days (120 hrs) was performed (A) to show that DMSO (used as the vehicle for OT-82) did not affect invasion in comparison to untreated cells and (B) to demonstrate the effects of OT-82 treatment at either 1 nM or 10 nM in comparison to vehicle alone (DMSO) or the non-invasive control (no serum in the lower chamber). In each case, a representative graph from one of three separate experiments is shown. (C) The invasion inhibition for three repeats at each dose is shown for each cell line. The average invasion inhibition is shown as a percentage compared to the vehicle alone (DMSO) invasion and T-tests were performed comparing each dose to the vehicle alone (DMSO).

4 February 2025
Verified
Other
Open access
PDF file
SNSusana S. Najera
Susana S. Najera
Christopher J. RickettsChristopher J. Ricketts
Christopher J. Ricketts
LSLaura S. Schmidt
Laura S. Schmidt
JMJulia I. Medina
Julia I. Medina
KSKeita Saito
Keita Saito
JMJordan L. Meier
Jordan L. Meier
Pharmacokinetic profile of OT-82 in nude and NSG mice. (A) Bioanalysis of plasma concentrations of OT-82 were made using a validated LC-MS/MS assay (n=3 nude mice, 50 mg/kg, 7 intervals; n=3 NSG mice, 75mg/kg, 7 intervals). (B) Pharmacokinetic parameters were calculated after a single dose of OT-82. The data from all mice in each group were pooled together to assume one “average” mouse per group.

4 February 2025
Verified
Other
Open access
PDF file
SNSusana S. Najera
Susana S. Najera
Christopher J. RickettsChristopher J. Ricketts
Christopher J. Ricketts
LSLaura S. Schmidt
Laura S. Schmidt
JMJulia I. Medina
Julia I. Medina
KSKeita Saito
Keita Saito
JMJordan L. Meier
Jordan L. Meier
In vitro analysis of NAMPT inhibition on glycolysis in FH-deficient tumor cells. (A) Effects of the NAMPT inhibitor OT-82 (100 nM) on the extracellular acidification rate (ECAR) in the UOK262 and UOK365 HLRCC cell lines and the RPTEC normal cell line. (B) Representation of the different effects of OT-82 versus DMSO at time point 5 (designated by a star) after the injection of glucose in UOK262, UOK365, and RPTEC. 2-DG, 2-deoxyglucose.

4 February 2025
Verified
Other
Open access
PDF file
SNSusana S. Najera
Susana S. Najera
Christopher J. RickettsChristopher J. Ricketts
Christopher J. Ricketts
LSLaura S. Schmidt
Laura S. Schmidt
JMJulia I. Medina
Julia I. Medina
KSKeita Saito
Keita Saito
JMJordan L. Meier
Jordan L. Meier
NAD+ and NADH analysis of UOK365 cells. Analysis of the relative levels of NAD+ and NADH and their ratio after 24 hour treatment of the UOK365 cell line model with a range of concentrations (0.5-100 nM) of either GNE-618 (A-B) or OT-82 (C-D). All levels were compared to cells treated with the amount of DMSO present in the highest concentration of the utilized drugs.